Lexaria Bioscience Corp. (NASDAQ: LEXX) is constantly collaborating with research institutions and businesses to identify new ways to innovate and improve its DehydraTECH(TM) drug-delivery technology. DehydraTECH is already being monetized through commercial use, and the company is utilizing advanced 2.0 formulations in ongoing human studies. A recent article discusses Lexaria’s move to consolidate the trading of its shares solely on the Nasdaq, and resulting advantages to the company and its shareholders. “Since it was listed back in January 2021, a substantial fraction of its shareholders moved onto this exchange. To them, it offered more liquidity than ever before, and to Lexaria, it presented an opportunity to realize savings in fees and managerial time,” the article reads. “The company’s management intends to direct the cost savings resulting from this move to its applied research and development programs, which would further advance the company’s business. Just earlier this year, Lexaria’s HYPER-A21-1 study resulted in the inclusion of three new DehydraTECH 2.0 formulation variations that would enable cannabidiol (‘CBD’) delivery performance enhancements as well as pharmacokinetic optimization. With more funding for such research, Lexaria is well-positioned to achieve even better results and better outcomes for its drug-delivery goals.”
To view the full article, visit https://ibn.fm/YfIp9
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes. It is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
